Expert Interviews

Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

The needle might be further pushed forward for precision medicine through exploration of novel proteins such as CDC37 and MAOB in patients with metastatic colorectal cancer.

Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.

A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.

Kim A. Reiss Binder, MD, spoke about the use of niraparib plus either nivolumab or ipilimumab for patients with platinum-sensitive advanced pancreatic adenocarcinoma.

Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.

A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.

Looking toward the future management of solid tumors with NRG1 fusions, expert panelists consider how the availability of seribantumab therapy may impact their practice.

Key opinion leaders in the management of breast cancer discuss the role of the radiation oncologist in treating patients with brain metastases.

Centralizing the conversation on trastuzumab deruxtecan, panelists comment on treatment toxicity and factors to consider when sequencing therapies in later lines of treatment.

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Roy Herbst, MD, PhD, provides insight on the importance of EGFR mutations, both common and rare, in patients with non–small cell lung cancer.

Expert perspectives on molecular profiling strategies that may help overcome barriers to testing in non–small cell lung cancer.

Valentina Boni, MD, PhD, spoke about the rationale behind using lurbinectedin monotherapy for pretreated BRCA1/2-associated metastatic breast cancer.

Saad Z. Usmani, MD, MBA, FACP, spoke about the safety profile of standard triplet therapy with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma in the phase 3 SWOG 1211 trial and how results of this trial may be used in future datasets to inform treatment in this setting.

C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Mark Pegram, MD, discussed the highlights from ASCO 2022, regarding antibody drug conjugates.

John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.

A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.

A brief review of key takeaways from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.